Raffa Wealth Management’s UroGen Pharma URGN Stock Holding History

Raffa Wealth Management’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-42	Closed	-$366	–	1171
2022 Q1	$366	Hold	42	–	–	﹤0.01%	1084
2021 Q4	$399	Hold	42	–	–	﹤0.01%	1085
2021 Q3	$706	Buy	+42	New	+$666	﹤0.01%	966

Other funds holding URGN

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Millennium Management

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

Raffa Wealth Management's URGN Position: Q2 2022 in Review

Raffa Wealth Management sold out of UroGen Pharma (URGN) in Q2 2022, closing a stake of 42 shares — an estimated $366 sold.

Raffa Wealth Management first reported a position in URGN in Q3 2021 and held it in 3 quarters. The position peaked at $706 in Q3 2021. 65 funds tracked by Wall St. Rank hold URGN as of Q2 2022.

Raffa Wealth Management reported no remaining UroGen Pharma position as of Q2 2022 after selling out during the quarter.
Raffa Wealth Management sold 42 UroGen Pharma shares in Q2 2022, an estimated $366.
Raffa Wealth Management first reported a position in UroGen Pharma in Q3 2021 and held it in 3 quarters.
Raffa Wealth Management's UroGen Pharma position peaked at $706 in Q3 2021.
65 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2022.

Based on Raffa Wealth Management's 13F filing for Q2 2022, filed 27 Jul 2026.